| Followers | 3 |
| Posts | 238 |
| Boards Moderated | 0 |
| Alias Born | 10/24/2024 |
Recent ALLO News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:41:34 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 08:40:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:37:36 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/23/2026 09:33:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:16:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 12:22:29 AM
- Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 09:21:13 PM
- Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock • GlobeNewswire Inc. • 04/16/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 08:35:50 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/15/2026 08:33:15 PM
- Allogene Publishes Promising ALLO-329 Data in Nature Communications • IH Market News • 04/15/2026 02:59:55 PM
- Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases • GlobeNewswire Inc. • 04/15/2026 12:30:00 PM
- Allogene Therapeutics Announces Pricing of Public Offering of Common Stock • GlobeNewswire Inc. • 04/15/2026 01:50:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/13/2026 08:44:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 08:09:04 PM
- Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock • GlobeNewswire Inc. • 04/13/2026 08:01:00 PM
- Allogene shares jump on encouraging ALPHA3 trial update • IH Market News • 04/13/2026 02:13:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 11:45:15 AM
- Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL • GlobeNewswire Inc. • 04/13/2026 11:30:00 AM
- Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 • GlobeNewswire Inc. • 04/10/2026 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:47:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 11:13:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:06:54 PM
